What is Contineum Therapeutics's earnings per share (EPS)?

Contineum Therapeutics (CTNM) reported diluted earnings per share of $-2.17 for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Contineum Therapeutics Financials

CTNM

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Contineum Therapeutics (CTNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CTNM FY2025 2026-05-05

Equity financing rather than product revenue is funding a research-heavy, asset-light operating model as cash burn steepens.

From FY2024 to FY2025, operating cash burn widened from -$32.8M to -$55.3M, yet cash rose from $21.9M to $75.6M because financing inflows exceeded $109.0M in both years. That combination means current balance-sheet strength comes from external capital raising, not from the business turning research spending into self-funding operations.

FY2025 capital spending was only $231K against -$55.5M of free cash flow, so this is not a facilities build-out story; the cash need sits mainly inside R&D and operating expense, with research spending alone at $51.5M. In practice, the burn reflects how aggressively the company is funding development activity rather than how much equipment it must buy.

With total liabilities of just $15.7M against $276.6M of assets and debt-to-equity at 0.06x, the company is lightly levered even after retained earnings fell to -$177.4M. The key constraint visible in the statements is cash consumption, not pressure from lenders or a debt-heavy capital structure.

Financial Health Signals

Financial Profile 66/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Contineum Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Contineum Therapeutics carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 27.50, Contineum Therapeutics holds $27.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Contineum Therapeutics generates a -23.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -21.3% the prior year.

Piotroski F-Score Weak

2/9

Contineum Therapeutics passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, Contineum Therapeutics generates $0.92 in operating cash flow (-$55.3M OCF vs -$60.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$67.7M

YoY-33.8%

Contineum Therapeutics's EBITDA was -$67.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.8% from the prior year.

Net Income

-$60.0M

YoY-41.9%

Contineum Therapeutics reported -$60.0M in net income in fiscal year 2025. This represents a decrease of 41.9% from the prior year.

EPS (Diluted)

$-2.17

YoY+0.5%

Contineum Therapeutics earned $-2.17 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$55.5M

YoY-66.5%

Contineum Therapeutics generated -$55.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 66.5% from the prior year.

Cash & Debt

$75.6M

YoY+244.5%

Contineum Therapeutics held $75.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-23.0%

YoY-1.6pp

Contineum Therapeutics's ROE was -23.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$51.5M

YoY+34.1%

Contineum Therapeutics invested $51.5M in research and development in fiscal year 2025. This represents an increase of 34.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$231K

YoY-55.1%

Contineum Therapeutics invested $231K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 55.1% from the prior year.

CTNM Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	$0-100.0%	$50.0M
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$51.5M+34.1%	$38.4M+39.2%	$27.6M
SG&A Expenses	$16.5M+32.6%	$12.5M+97.3%	$6.3M
Operating Income	-$68.1M-33.7%	-$50.9M-416.6%	$16.1M
Interest Expense	N/A	$0-100.0%	$208K
Income Tax	$0	$0-100.0%	$450K
Net Income	-$60.0M-41.9%	-$42.3M-286.0%	$22.7M
EPS (Diluted)	$-2.17+0.5%	$-2.18-2825.0%	$0.08

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.6M	N/A	$11.0M-21.8%	$14.1M+2.6%	$13.7M	N/A	$9.7M+23.1%	$7.9M
SG&A Expenses	$5.3M	N/A	$3.9M+2.6%	$3.8M-12.7%	$4.4M	N/A	$3.2M+6.7%	$3.0M
Operating Income	-$16.9M	N/A	-$14.9M+16.6%	-$17.9M+1.1%	-$18.1M	N/A	-$13.0M-18.5%	-$10.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Net Income	-$14.5M	N/A	-$12.8M+20.2%	-$16.0M-0.3%	-$16.0M	N/A	-$10.3M-14.0%	-$9.0M
EPS (Diluted)	$-0.39	N/A	N/A	N/A	$-0.62	N/A	$-0.40-2.6%	$-0.39

CTNM Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$276.6M+30.0%	$212.8M+63.2%	$130.4M
Current Assets	$267.9M+29.8%	$206.4M+61.6%	$127.7M
Cash & Equivalents	$75.6M+244.5%	$21.9M+41.3%	$15.5M
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$15.7M+5.9%	$14.8M-92.5%	$198.3M
Current Liabilities	$9.7M-2.3%	$10.0M+81.9%	$5.5M
Long-Term Debt	N/A	N/A	N/A
Total Equity	$261.0M+31.8%	$198.1M+391.5%	-$67.9M
Retained Earnings	-$177.4M-51.1%	-$117.4M-56.2%	-$75.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$261.3M-5.5%	$276.6M+45.0%	$190.8M+4.4%	$182.9M-7.8%	$198.3M-6.9%	$212.8M-1.5%	$216.0M-2.4%	$221.4M
Current Assets	$253.0M-5.6%	$267.9M+44.9%	$184.9M+4.6%	$176.8M-8.0%	$192.1M-6.9%	$206.4M-4.1%	$215.1M-2.3%	$220.3M
Cash & Equivalents	$20.2M-73.3%	$75.6M+77.3%	$42.6M+105.1%	$20.8M-7.5%	$22.5M+2.4%	$21.9M-46.3%	$40.9M-47.1%	$77.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.3M-27.8%	$15.7M+50.8%	$10.4M-9.7%	$11.5M-14.8%	$13.5M-8.7%	$14.8M+154.6%	$5.8M+50.7%	$3.9M
Current Liabilities	$6.7M-31.7%	$9.7M+53.2%	$6.4M-11.8%	$7.2M-19.4%	$8.9M-10.3%	$10.0M+71.8%	$5.8M+55.3%	$3.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$250.0M-4.2%	$261.0M+44.6%	$180.5M+5.3%	$171.4M-7.2%	$184.8M-6.7%	$198.1M-5.8%	$210.2M-3.3%	$217.5M
Retained Earnings	-$191.8M-8.1%	-$177.4M-9.3%	-$162.2M-8.6%	-$149.4M-12.0%	-$133.4M-13.6%	-$117.4M-14.2%	-$102.8M-11.1%	-$92.6M

CTNM Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$55.3M-68.4%	-$32.8M-269.8%	$19.3M
Capital Expenditures	$231K-55.1%	$514K+24.2%	$414K
Free Cash Flow	-$55.5M-66.5%	-$33.4M-276.2%	$18.9M
Investing Cash Flow	-$3.7M+94.7%	-$69.7M-6.4%	-$65.6M
Financing Cash Flow	$112.7M+3.4%	$109.0M+94.0%	$56.2M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$28K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$16.3M-24.7%	-$13.0M-6.9%	-$12.2M+22.1%	-$15.7M-8.7%	-$14.4M-41.3%	-$10.2M-65.4%	-$6.2M+27.4%	-$8.5M
Capital Expenditures	$312K+642.9%	$42K-57.1%	$98K+122.7%	$44K-6.4%	$47K-71.7%	$166K+102.4%	$82K-31.1%	$119K
Free Cash Flow	-$16.6M-26.7%	-$13.1M-6.4%	-$12.3M+21.7%	-$15.7M-8.6%	-$14.5M-39.5%	-$10.4M-65.9%	-$6.3M+27.5%	-$8.6M
Investing Cash Flow	-$39.3M+17.2%	-$47.5M-417.6%	$14.9M+7.6%	$13.9M-6.9%	$14.9M+258.9%	-$9.4M+68.9%	-$30.2M+22.4%	-$38.9M
Financing Cash Flow	$129K-99.9%	$93.5M+389.2%	$19.1M+20894.5%	$91K+279.2%	$24K-96.3%	$642K+4838.5%	$13K-100.0%	$108.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CTNM Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	32.1%
Net Margin	N/A	N/A	45.4%
Return on Equity	-23.0%-1.6pp	-21.3%	N/A
Return on Assets	-21.7%-1.8pp	-19.9%-37.3pp	17.4%
Current Ratio	27.50+6.8	20.69-2.6	23.29
Debt-to-Equity	0.06-0.0	0.07+3.0	-2.92
FCF Margin	N/A	N/A	37.9%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-5.8%	N/A	-7.1%+2.3pp	-9.4%-0.7pp	-8.6%	N/A	-4.9%-0.7pp	-4.1%
Return on Assets	-5.5%	N/A	-6.7%+2.1pp	-8.8%-0.7pp	-8.1%	N/A	-4.8%-0.7pp	-4.1%
Current Ratio	38.00+10.5	27.50-1.6	29.07+4.6	24.51+3.0	21.47+0.8	20.69-16.4	37.06-21.9	58.92
Debt-to-Equity	0.05-0.0	0.060.0	0.060.0	0.070.0	0.070.0	0.07+0.0	0.030.0	0.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tectonic Therapeutic Inc TECX

$538.1M

Aldeyra Therapeutics Inc ALDX

$95.9M

Larimar Therapeutics Inc LRMR

$370.9M

Immuneering Corp IMRX

$337.7M

Design Therapeutics, Inc. DSGN

$687.7M

Frequently Asked Questions

Is Contineum Therapeutics profitable?

No, Contineum Therapeutics (CTNM) reported a net income of -$60.0M in fiscal year 2025.

What is Contineum Therapeutics's EBITDA?

Contineum Therapeutics (CTNM) had EBITDA of -$67.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Contineum Therapeutics's return on equity (ROE)?

Contineum Therapeutics (CTNM) has a return on equity of -23.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Contineum Therapeutics's free cash flow?

Contineum Therapeutics (CTNM) generated -$55.5M in free cash flow during fiscal year 2025. This represents a -66.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Contineum Therapeutics's operating cash flow?

Contineum Therapeutics (CTNM) generated -$55.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Contineum Therapeutics's total assets?

Contineum Therapeutics (CTNM) had $276.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Contineum Therapeutics's capital expenditures?

Contineum Therapeutics (CTNM) invested $231K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Contineum Therapeutics spend on research and development?

Contineum Therapeutics (CTNM) invested $51.5M in research and development during fiscal year 2025.

What is Contineum Therapeutics's current ratio?

Contineum Therapeutics (CTNM) had a current ratio of 27.50 as of fiscal year 2025, which is generally considered healthy.

What is Contineum Therapeutics's debt-to-equity ratio?

Contineum Therapeutics (CTNM) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Contineum Therapeutics's return on assets (ROA)?

Contineum Therapeutics (CTNM) had a return on assets of -21.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Contineum Therapeutics's cash runway?

Based on fiscal year 2025 data, Contineum Therapeutics (CTNM) had $75.6M in cash against an annual operating cash burn of $55.3M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Contineum Therapeutics's Piotroski F-Score?

Contineum Therapeutics (CTNM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Contineum Therapeutics's earnings high quality?

Contineum Therapeutics (CTNM) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Contineum Therapeutics?

Contineum Therapeutics (CTNM) scores 66 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.